

ASX Release  
21 September 2023

ASX Code: MEM

## **In-depth Investor Webinar Presentation**

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), is pleased to invite shareholders to an investor webinar scheduled for **Thursday 21<sup>st</sup> September 2023 at 2:30pm AEST/ 12:30pm AWST.**

Memphasys Managing Director and Chief Executive Officer Alison Coutts will provide a comprehensive overview of the Memphasys business and an updated of the Company's diverse product suite.

During the presentation, attendees will have the opportunity to pose questions to Ms Coutts - as well as Director of Operations Hassan Bakos, Director Business Development David Ali and Scientific Director Professor John Aitken - during moderated product-focussed Q&A sessions.

If you have questions you would like asked, please submit them to David Tasker (Chapter One Advisors) via email provided below.

To attend the live Zoom webinar, please register via the link below. A recorded copy will be made post the event.

[https://us02web.zoom.us/webinar/register/WN\\_OmmSVIWnQ8-E2Y9whM\\_d6Q](https://us02web.zoom.us/webinar/register/WN_OmmSVIWnQ8-E2Y9whM_d6Q)

This announcement has been approved for release by the board of Memphasys Limited.

### **ENDS**

For further information, please contact:

Alison Coutts  
Managing Director / Chief Executive Officer  
Memphasys Limited  
Tel: +61 2 8415 7300  
E: [alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors  
Tel: +61 433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

### **About Memphasys**

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

**Website:** [www.memphasys.com](http://www.memphasys.com)

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.